Compare Novartis AG (NVS) vs Procter & Gamble Co (PG) Price & Performance

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and a strong net margin of 18.44%. Recent earnings have consistently beaten expectations, and a dividend of $1.09 per share is scheduled for payment in August 2026. Analyst consensus is bullish with a price target of $161.20, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.

PG offers stability with consistent earnings beats and a reliable dividend, but premium valuations and soft demand outlook pose near-term risks. Supply chain improvements and brand partnerships provide growth catalysts, while economic sensitivity and competitive pressures remain headwinds. The stock presents a balanced opportunity for income-focused investors seeking defensive exposure amid market volatility.